BioGeneration Ventures said today its BGV III fund raised $95.4 million (EU €82 million) in its final closing, looking to focus on therapeutics, medical devices and diagnostics within the European Union. Investors joining the funding, which surpassed its $58.3 million (EU €50 million) including Bristol-Myers Squibb, Johnson & Johnson Innovation, the incubation arm of healthcare giant Johnson […]